Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
0(0%)
Results Posted
44%(4 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_4
3
30%
Ph phase_3
2
20%
Ph phase_1
1
10%
Ph phase_2
4
40%

Phase Distribution

1

Early Stage

4

Mid Stage

5

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
4(40.0%)
Phase 3Large-scale testing
2(20.0%)
Phase 4Post-market surveillance
3(30.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(9)
Terminated(1)

Detailed Status

Completed9
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
90.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (10.0%)
Phase 24 (40.0%)
Phase 32 (20.0%)
Phase 43 (30.0%)

Trials by Status

completed990%
terminated110%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_4

Stage I Multiple Myeloma Treatment

NCT00733538
completedphase_2

Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy

NCT00582556
completedphase_2

Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)

NCT01204203
completedphase_1

Investigation of Changes in Bone Scan Imaging Before and After Intravenous Bisphosphonate Therapy for Osseous Metastases From Breast Cancer

NCT00582920
completedphase_2

Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide

NCT00083382
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT00733538Phase 4

Stage I Multiple Myeloma Treatment

Completed
NCT00582556Phase 2

Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy

Completed
NCT01204203Phase 2

Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)

Completed
NCT00582920Phase 1

Investigation of Changes in Bone Scan Imaging Before and After Intravenous Bisphosphonate Therapy for Osseous Metastases From Breast Cancer

Completed
NCT00083382Phase 2

Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide

Completed
NCT00712985Phase 3

Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL)

Completed
NCT00762346Phase 4

Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis

Completed
NCT00242203Phase 2

Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer

Completed
NCT00294437Phase 3

ZOMETA® (Zoledronic Acid) for Prevention of Bone Metastases

Terminated
NCT00035997Phase 4

Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis

Completed

All 10 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
10